Federated Hermes, Inc. Cabaletta Bio, Inc. Transaction History
Federated Hermes, Inc.
- $50.2 Billion
- Q2 2025
A detailed history of Federated Hermes, Inc. transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 344,540 shares of CABA stock, worth $813,114. This represents 0.0% of its overall portfolio holdings.
Number of Shares
344,540
Previous 343,411
0.33%
Holding current value
$813,114
Previous $477,000
9.64%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CABA
# of Institutions
94Shares Held
77.1MCall Options Held
406KPut Options Held
90.9K-
Bain Capital Life Sciences Investors, LLC Boston, MA9.68MShares$22.8 Million4.41% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.83MShares$20.8 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.79MShares$16 Million0.01% of portfolio
-
Jennison Associates LLC6.02MShares$14.2 Million0.01% of portfolio
-
Cormorant Asset Management, LP Boston, MA5MShares$11.8 Million0.77% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $68.5M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...